UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-QSB
(Mark One)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934 [Fee Required]
For the quarterly period ended - June 30, 2000
[-] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934 [No Fee Required]
For the transition period from ________ to ________
Commission file number 33-33042-NY
CORONADO INDUSTRIES, INC.
----------------------------------------------
(Name of small business issuer in its charter)
Nevada 22-3161629
--------------------------------- ------------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
16929 E. Enterprise Drive, Suite 202, Fountain Hills, AZ 85268
--------------------------------------------------------------- ----------
(Address of Principal executive offices) (as of date of filing) (Zip Code)
Issuer's telephone number (480) 837-6810
---------------
Check whether the issuer (1) filed all reports required to be filed by
section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the Registrant was required to file such reports), and (2)
has been subject such filing requirements for the past 90 days. Yes [X] No [ ]
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS
Check whether the registrant filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by court. Yes [ ] No [ ]
APPLICABLE ONLY TO CORPORATE ISSUERS
State the number of shares outstanding of each of the issuer's classes of
common equity, as of June 30, 2000: 34,986,337
Transitional Small Business Disclosure Format (check one): Yes [ ] No [X]
<PAGE>
CORONADO INDUSTRIES, INC.
FORM 10-QSB
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2000
Page
----
PART I
Item 1 Financial Statements 3
Item 2. Management's Discussion and Analysis or Plan of Operation 9
PART II
Item 1. Legal Proceedings 12
Item 2. Changes in Securities N/A
Item 3. Defaults Upon Senior Securities N/A
Item 4. Submission of Matter to a Vote of Security Holders N/A
Item 5. Other Matters N/A
Item 6. Exhibits and Reports on Form 8-K 12
SIGNATURES 13
2
<PAGE>
CORONADO INDUSTRIES, INC.
BALANCE SHEETS
JUNE 30, 2000 AND DECEMBER 31, 1999
June 30, December 31,
2000 1999
----------- -----------
(Unaudited) (Audited)
ASSETS
Current Assets:
Cash $ 44,000 $ 3,454
Inventory 24,265 24,265
Prepaid Expenses 0 0
----------- -----------
Total Current Assets 68,265 27,719
Property and Equipment, net 108,378 115,767
Other Assets:
Intangible Assets, net 26,956 28,833
Deferred Loan Expense 23,000 26,000
Deposits 0 0
----------- -----------
Total Assets $ 226,599 $ 198,319
=========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current Liabilities:
Note Payable to Related Party -
Current Portion $ 225,407 $ 79,960
Accounts Payable 42,370 94,252
Accrued Salaries 444,474 276,090
Stock Warrant Deposits (Note 3) 75,000 0
Other Liabilities 18,316 2,835
----------- -----------
Total Current Liabilities 805,567 453,137
Long-term Debt 230,000 230,000
----------- -----------
Total Liabilities 1,035,567 683,137
----------- -----------
Stockholders' Equity (Deficit):
Preferred Stock - $.0001 par value: 3,000,000
shares authorized, none issued or outstanding 0 0
Common Stock - $.001 par value;
50,000,000 shares authorized, 34,986,337
shares outstanding at June 30, 2000;
33,385,046 outstanding at December 31, 1999 34,986 33,385
Additional Paid-in Capital 4,036,835 3,170,378
Accumulated Deficit (4,880,789) (3,688,581)
----------- -----------
Total Stockholders' Equity (Deficit) (808,968) (484,818)
----------- -----------
Total Liabilities and Stockholders'
Equity (Deficit) $ 226,599 $ 198,319
=========== ===========
3
<PAGE>
CORONADO INDUSTRIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
SIX AND THREE MONTHS ENDED JUNE 30, 2000 AND 1999
(UNAUDITED)
<TABLE>
<CAPTION>
Six Months Three Months
------------------------------ ------------------------------
2000 1999* 2000 1999*
------------ ------------ ------------ ------------
(Unaudited) (Unaudited) (Unaudited) (Unaudited)
<S> <C> <C> <C> <C>
Product Revenues $ -- $ 46,000 $ -- $ --
Patient Revenues 0 28,005 0 --
------------ ------------ ------------ ------------
Total Revenues 0 74,005 0 --
Cost of Product Revenues 0 125,150 121,250
Cost of Patient Revenues 0 48,468 --
------------ ------------ ------------ ------------
Total Cost of Revenues 0 173,618 0 121,250
------------ ------------ ------------ ------------
Gross Profit/(Loss) 0 (99,613) 0 (121,250)
General and Administrative Expenses:
Salaries and Wages 231,848 125,000 118,278 86,976
Public Relations 546,250 73,080 56,000 63,080
Legal and Professional fees 151,215 79,994 48,398 33,045
FDA expenses 97,539 66,668 72,333 50,000
Rent expense 42,241 0 19,337 0
Miscellaneous expenses 86,157 205,207 36,012 143,098
------------ ------------ ------------ ------------
Total general and administrative expenses 1,155,250 549,949 350,358 376,199
Loss from Operations (1,155,250) (649,562) (350,358) (497,449)
------------ ------------ ------------ ------------
Interest Income (Expense) (38,732) (8,895) (20,603) (8,295)
Deferred Loan Expense (3,000) (1,000) (1,500) (1,000)
Other Income (Expense) 4,774 111,000 2,024 111,000
------------ ------------ ------------ ------------
Net Loss (1,192,208) (548,457) (370,437) (395,744)
============ ============ ============ ============
Basic Loss per Share $ (0.03) $ (0.02) $ (0.01) $ (0.01)
============ ============ ============ ============
Weighted Average Shares Outstanding 34,473,431 31,921,774 35,326,348 31,954,432
============ ============ ============ ============
</TABLE>
* As restated, for comparative purposes only.
4
<PAGE>
CORONADO INDUSTRIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE THREE MONTHS ENDED JUNE 30, 2000 AND 1999
June 30, 2000 June 30, 1999
--------- ---------
(Unaudited) (Unaudited)
CASH FLOW FROM OPERATING ACTIVITIES:
Cash received from customers $ 2,024 $ 0
Cash paid to suppliers and employees (42,553) (203,843)
Interest paid (12,150) 0
--------- ---------
Net cash used by operating activities (52,679) (203,843)
--------- ---------
CASH FLOW USED IN INVESTING ACTIVITIES:
Acquisition of property and equipment 0 0
Sale of building 0 111,000
Deposits on fixed assets 7,750 0
--------- ---------
Net cash used by investing activities 7,750 111,000
--------- ---------
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from borrowings 0 246,000
Repayment of notes payable 0 (40,000)
Loan origination fee 0 (30,000)
Deposit on stock warrants 75,000 0
Cash received from sale of common stock 0 0
--------- ---------
Net cash provided by financing activities 75,000 176,000
--------- ---------
NET INCREASE IN CASH 30,071 83,157
CASH, beginning of period 13,929 8,211
--------- ---------
CASH, end of period $ 44,000 $ 91,368
========= =========
RECONCILIATION OF NET LOSS TO NET CASH USED
BY OPERATING ACTIVITIES:
Net Loss $(370,438) $(395,744)
--------- ---------
Adjustments to reconcile net loss to net cash used
by operating activities:
Depreciation 7,450 7,900
Amortization 939 939
Stock issued for services 148,537 180,679
Stock issued for salaries 20,238 0
(Gain) on sale of building 0 (111,000)
Interest added to principal of notes payable 8,452 0
Changes in Assets and Liabilities:
(Increase)/Decrease
Accounts receivable 0 32,469
Prepaid expenses 0 4,345
Inventory 0 0
Deferred Loan 1,500 1,000
Increase/(Decrease)
Accounts payable 35,981 569
Accrued salaries 87,083 75,000
Accrued payroll taxes and other 7,579 0
--------- ---------
317,759 191,901
--------- ---------
Net Cash Used by Operating Activities $ (52,679) $(203,843)
========= =========
5
<PAGE>
CORONADO INDUSTRIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2000 AND 1999
June 30, 2000 June 30, 1999
----------- -----------
(Unaudited) (Unaudited)
CASH FLOW FROM OPERATING ACTIVITIES:
Cash received from customers $ 4,774 $ 0
Cash paid to suppliers and employees (168,094) (256,476)
Interest paid (24,300) 0
----------- -----------
Net cash used by operating activities (187,620) (256,476)
----------- -----------
CASH FLOW USED IN INVESTING ACTIVITIES:
Acquisition of property and equipment (7,281) 0
Sale of building 0 111,000
Deposits on fixed assets 0 0
----------- -----------
Net cash used by investing activities (7,281) 111,000
----------- -----------
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from borrowings 239,160 230,000
Repayment of notes payable (93,713) 0
Loan origination fee 0 (30,000)
Deposit on stock warrants 75,000 0
Cash received from sale of common stock 15,000 0
----------- -----------
Net cash provided by financing activities 235,447 200,000
----------- -----------
NET INCREASE (DECREASE) IN CASH 40,546 54,524
CASH, beginning of period 3,454 36,844
----------- -----------
CASH, end of period $ 44,000 $ 91,368
=========== ===========
RECONCILIATION OF NET LOSS TO NET CASH USED
BY OPERATING ACTIVITIES:
Net Loss $(1,192,208) $ (548,457)
----------- -----------
Adjustments to reconcile net loss to net cash used
by operating activities:
Depreciation 14,670 15,800
Amortization 1,878 1,878
Stock issued for services 798,792 196,457
Stock issued for salaries 54,263 0
(Gain) on sale of building 0 (111,000)
Interest added to principal of notes payable 14,431 0
Changes in Assets and Liabilities:
(Increase)/Decrease
Accounts receivable 0 30,148
Prepaid expenses 0 22,490
Inventory 0 600
Deferred Loan 3,000 1,000
Increase/(Decrease)
Accounts payable (51,882) 9,608
Accrued salaries 162,083 125,000
Accrued payroll taxes and other 7,353 0
----------- -----------
1,004,588 291,981
----------- -----------
Net Cash Used by Operating Activities $ (187,620) $ (256,476)
=========== ===========
6
<PAGE>
CORONADO INDUSTRIES, INC.
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)
For The Six Month Period Ended June 30, 2000
<TABLE>
<CAPTION>
Total
Common Stock Stock-
---------------------- Additional Retained Holders'
Shares Paid-in Earnings Equity
Outstanding Amount Capital (Deficit) (Deficit)
----------- ------ ------- --------- ---------
<S> <C> <C> <C> <C> <C>
Balance at December 31, 1999 33,385,046 $ 33,385 $ 3,170,378 $(3,688,581) $ (484,818)
Stock issued for services 1,344,373 1,344 797,451 -- 798,795
Stock issued for salaries 56,918 57 54,206 -- 54,263
Stock options exercised 200,000 200 14,800 -- 15,000
Net loss -- -- -- (1,192,208) (1,192,208)
----------- -------- ----------- ----------- -----------
Balance at June 30,2000 34,986,337 $ 34,986 $ 4,036,835 $(4,880,789) $ (808,968)
=========== ======== =========== =========== ===========
</TABLE>
7
<PAGE>
CORONADO INDUSTRIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
1. SIGNIFICANT ACCOUNTING POLICIES:
BASIS OF PRESENTATION:
In the opinion of management, the accompanying financial statements reflect all
adjustments (consisting of normal recurring accruals) necessary to present
fairly the Company's financial position as of June 30, 2000 and the results of
its operations for the six and three months ended June 30, 2000. Although
management believes that the disclosures in these financial statements are
adequate to make the information presented not misleading, certain information
and footnote disclosures normally included in financial statements that have
been prepared in accordance with generally accepted accounting principles have
been condensed or omitted pursuant to the rules and regulations of the
Securities Exchange Commission.
The results of operations for the six months ended June 30, 2000 are not
necessarily indicative of the results that may be expected for the full year
ending December 31, 2000. The accompanying consolidated financial statements
should be read in conjunction with the more detailed financial statements, and
the related footnotes thereto, filed with the Company's Annual Report on Form
10-KSB for the year ended December 31, 1999.
PRINCIPLES OF CONSOLIDATION:
The consolidated financial statements include the financial position, results of
operations, cash flows and changes in stockholders' equity of Coronado
Industries, Inc., and its wholly-owned subsidiaries. All material intercompany
transactions, accounts and balances have been eliminated.
USE OF ESTIMATES IN THE PREPARATION OF FINANCIAL STATEMENTS:
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimates.
2. BASIC LOSS PER SHARE:
For the six month period ending June 30, 2000, basic loss per share includes no
dilution and is computed by dividing income available to common stockholders by
the weighted average number of common shares outstanding for the period. Diluted
earnings per share are not presented as their affect is antidilutive.
3. STOCK WARRANT DEPOSITS:
Effective May 16, 2000, the Company entered into an agreement with an existing
warrant holder to modify the terms and conditions of his warrants. Pursuant to
the new agreement, the exercise price of the warrants was reduced from $2.50 per
share to $0.75 per share on 519,000 warrants, for a total exercise price of
$389,250. The warrant holder was required to deposit $50,000 earnest money with
completion of the funding due by June 15, 2000. The Company subsequently agreed
to extend the due date to July 17, 2000, and received an additional $25,000
deposit prior to June 30, 2000.
Subsequent to June 30, 2000, the Company agreed to an additional extension of
the due date to September 1, 2000 and received an additional $25,000 deposit.
Should the warrant holder be unable to pay the balance due of $289,250 on
September 1, 2000, the total deposit of $100,000 would be forfeited to the
Company.
8
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
SPECIAL NOTE ON FORWARD-LOOKING STATEMENTS
Except for historical information contained herein, this document contains
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities
Exchange Act of 1934, as amended (the "Exchange Act") and the Company intends
that such forward-looking statements be subject to the safe harbors created
thereby. Such forward-looking statements involve risks and uncertainties and
include, but are not limited to, statements regarding future events and the
Company's plans and expectations. The Company's actual results may differ
materially from such statements. Although the Company believes that the
assumptions underlying the forward-looking statements herein are reasonable, any
of the assumptions could prove inaccurate and, therefore, there can be no
assurance that the results contemplated in such forward-looking statements will
be realized. In addition, the business and operations of the Company are subject
to substantial risks which increase the uncertainties inherent in the
forward-looking statements included in this document. The inclusion of such
forward-looking information should not be regarded as a representation by the
Company or any other person that the future events, plans or expectations
contemplated by the Company will be achieved.
YEAR 2000 ISSUES
The Company believes its present operations are Year 2000 compliant because the
Company's current use of computers on the headquarters level is minimal and the
primary customer of the Company's treatment centers is the federal government.
At the headquarters level the Company's computers are used exclusively for word
processing, as opposed to accounting, functions. Since the Company's present and
future product sales will be done on a cash-on-delivery or pre-paid basis, the
Company will have no significant accounts receivable for product sales. All of
the Company's employee payroll functions are handled by a nationwide third-party
vendor which has advised the Company that its operations are Year 2000
compliant.
With respect to the Company's treatment centers, the Company purchased a
computer software system in December 1997 which was represented as Year 2000
compliant and the Company's computers purchased in 1997 use an operating system
which is represented as Year 2000 compliant. At this time the Company believes
the risks to its operations from a Year 2000 problem are minimal.
QUARTER ENDING JUNE 30, 2000
For the quarter ending June 30, 2000 Registrant experienced a net loss of
$370,437, which was comprised primarily of its general and administrative
expenses incurred at the corporate level of $350,358 and net interest expense of
$20,603. 77.2% of Registrant's second quarter 2000 general and administrative
9
<PAGE>
expenses consisted of officers salaries of $93,750 (26.89%), professional
expenses of $120,731 (34.5%) and shareholder services and media promotion of
$56,000 (15.9%). In comparison, during second quarter 1999 58.8% of Registrant's
general and administrative expense of $376,199 consisted of officers' salaries
of $75,000 (19.9%), professional expenses of $83,045 (22.0%) and shareholder
services and media promotion of $63,080 (16.8%). The increase in officer's
salaries in 2000 over 1999 resulted from Dr. LiVecchi receiving an accrued
salary in April, 2000. The increases in professional expenses in 2000 over 1999
occurred as a result of Dr. Bores being involved in the FDA application process
full time in 2000 and increased legal expenses incurred in the FDA application
process. Over 80% of the corporate expenses in 2000 were paid with Registrant's
common stock in order to preserve Registrant's cash resources. Registrant
expects its management salaries to increase in the second half of 2000 because
on April 1, 2000 Dr. LiVecchi was granted an annual salary of $75,000 and
Registrant will be required to appoint as many as two new outside Directors in
2000 in order to obtain listing for its stock on the NASD NMS or Small Cap
market. Registrant expects its professional expenses in 2000 to remain at a high
level as a result of its continuing costs for its FDA application presently
estimated at $15,000 per month. As Registrant continues its foreign marketing
efforts in 2000, its promotional expenses will likely remain high.
The Registrant currently plans on opening its Clearwater treatment center within
three months of securing the services of a suitable medical director and
obtaining sufficient financing for the center (see below). The Registrant is
hopeful, without any assurance, that the right physician will be able to make
the Clearwater treatment center much more profitable than the Scottsdale center.
However, the Registrant will incur substantial travel expenses in the future in
managing the Clearwater treatment center, expenses which were not involved in
managing the Scottsdale treatment center.
SIX MONTHS ENDING JUNE 30, 2000
OPERATIONS. Since Registrant closed its Scottsdale glaucoma treatment center on
March 2, 1999, the first half of the 2000 fiscal year can not be compared to the
operations for the first half of 1999.
For the six months ending June 30, 2000 Registrant experienced a net loss of
$1,192,208, which was comprised primarily of its general and administrative
expenses incurred at the corporate level of $1,155,250 and net interest expense
of $38,732. 88.9% of Registrant's 2000 first half corporate expenses consisted
of officers' salaries of $231,848 (20.1%), professional expenses of $248,754
(21.5%) and shareholder services and media promotion of $546,250 (47.3%). In
comparison, during the first half of 1999 62.7% of Registrant's corporate
expense of $549,949 consisted of officers' salaries of $125,000 (22.7%),
professional expenses of $146,662 (26.7%) and shareholder services and media
promotion of $73,080 (13.3%). The increase in officers' salaries for 2000 over
1999 occurred as a result of two officers' salary was increased in April 1999 by
$50,000 and Dr. LiVecchi started receiving an accrued salary of $75,000 in April
2000. The increase in professional expenses in 2000 over 1999 occurred as a
result of Dr. Bores being involved in the FDA application process full time in
2000 and the increased legal expenses incurred in the FDA application process
and listing Registrant's stock for trading on a German exchange in the first
quarter 2000. The increase in shareholder services and media promotion in 2000
over 1999 resulted from an agreement with a new shareholder relations firm being
reached in 2000 and the commencement of a European product marketing campaign in
the first quarter of 2000. Over 80% of the corporate expenses in 2000 were paid
with Registrant's common stock in order to preserve Registrant's cash resources.
Registrant expects its management salaries to increase in the second half of
2000 because on April 1, 2000 Dr. LiVecchi was granted an annual salary of
$75,000 and Registrant will be required to appoint as many as two new outside
Directors in 2000 in order to obtain listing for its stock on the NASD NMS or
Small Cap market. Registrant expects its professional expenses in 2000 to remain
at a high level as a result of its continuing costs for its FDA application
presently estimated at $15,000 per month. As Registrant continues its foreign
marketing efforts in 2000, its promotional expenses will likely remain high.
10
<PAGE>
LIQUIDITY AND CAPITAL RESOURCES. On a short-term and long-term basis Registrant
requires only minimal capital to sustain its manufacturing of the patented
equipment, because of Registrant's current inventory levels. Because of the
Registrant's cash position at year-end and general and administrative cash
expenses totaling approximately $187,620, Registrant suffered from a liquidity
shortage during the first half of 2000. Registrant was required to borrow a
total of $225,407 through June 30, 2000 from its two officers, Richard and Gary
Smith. Unless substantial product sales are achieved in the near future,
Registrant will continue to experience a liquidity shortage. There can be no
assurance as to when Registrant's product will be approved for sale in the
United States by the FDA or when foreign sales will commence in a substantial
manner. Registrant will likely be forced to borrow additional funding from its
management throughout the remainder of 2000; however, there is no assurance
Registrant will be able to obtain any financing in the future.
Registrant also requires approximately $400,000 to $600,000 to adequately fund
the first year's operation of its planned Clearwater glaucoma treatment center.
Registrant is presently planning to secure financing in 2000 to finance the
Clearwater treatment center. However, at this time Registrant has received no
commitments from any source to provide such financing and its financing sources
appear limited.
As a result of the presentation of the Registrant's patented equipment at the
various conventions of ophthalmologists in 1998 and 1999, the Registrant has
held discussions with potential distributors for the Registrant's product in the
U.S. and internationally on a non-exclusive and an exclusive basis. The
Registrant expects negotiations on one or more U.S. and European distribution
agreements to continue throughout 2000; however, there is no assurance that any
distribution contracts will ever be executed by the Registrant.
As of July 1, 2000 Registrant had warrants for over 1,300,000 shares of
Registrant's common stock held by some 25 individuals as a result of
Registrant's 1997 and 1998 private placements. These warrants have an exercise
price of $2.50 and an expiration date of December 31, 2000. Registrant is
hopeful that a substantial number of these warrants will be exercised in the
second half of 2000, if the stock underlying the warrants can be registered with
the SEC and the market price of Registrant's stock can rise above and remain at
$4.00 per share.
Registrant is hopeful it can acquire one or more assets or companies in 2000
which can provide Registrant with cashflow with which to fund its operations.
Registrant would attempt to finance such acquisitions with cash from the
exercise of outstanding warrants or its common stock. However, there is no
assurance that Registrant will be able to complete any acquisition in the
future. Additionally, compliance with state and federal securities laws may make
any attempted acquisitions time-consuming and expensive.
On a long-term basis, Registrant anticipates, without assurances, that the sale
of its product in the U.S. and internationally will provide sufficient liquidity
to the Registrant.
Through June 30, 2000 the Registrant received loans of approximately $112,500
from each of G. Richard Smith and Gary R. Smith, the Registrant's Chairman and
President, respectively. These loans accrue annual interest at the rate of 15%.
11
<PAGE>
PART II - OTHER INFORMATION
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
In February 2000, Registrant was served with a demand for arbitration in
San Diego, California by a former public relations firm of Registrant. This firm
claims a monetary debt of approximately $19,000 and the issuance of 300,000
shares of Registrant's common stock. Registrant does not deny the monetary debt,
but claims the written agreement with this public relations firm includes no
provision for the issuance of Registrant's stock. At this time there can be no
assurance of the outcome of this arbitration.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) EXHIBITS
27 - Financial Data Schedule
(b) REPORTS ON FORM 8-K
Registrant filed no reports on Form 8-K with the Commission during
the period ended June 30, 2000.
12
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto authorized.
CORONADO INDUSTRIES, INC.
Date: August 9, 2000 By: /s/ Gary R. Smith
-------------- ----------------------------------
Gary R. Smith, President (Chief
Executive Officer) and Treasurer
(Chief Accounting Officer)
13
